Clinical Laboratories of Hawaii, LLP, commonly referred to as CLH, is a leading provider of tissue-typing and cell processing services headquartered in the United States. Established in 1995, CLH has built a strong reputation across Hawaii and the Pacific region, specialising in immunogenetics and transplantation diagnostics. The laboratory offers a range of core services, including HLA typing, crossmatching, and cellular therapy processing, distinguished by their commitment to accuracy and rapid turnaround times. With state-of-the-art technology and a team of experienced professionals, CLH ensures high-quality results that support patient care and transplant success. Recognised for its excellence in the field, Clinical Laboratories of Hawaii has positioned itself as a trusted partner for healthcare providers, contributing significantly to advancements in transplant medicine and patient outcomes.
How does Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab's score of 58 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab currently does not have specific carbon emissions data available for the most recent year. As a merged entity, it inherits its climate commitments and emissions data from its parent organisation, Eurofins Scientific SE, at cascade level 4. While no absolute emissions figures are provided, Eurofins Scientific SE has established various climate initiatives, including Science Based Targets (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Clinical Laboratories of Hawaii are not detailed in the available information. The organisation's commitment to sustainability aligns with industry standards, reflecting a broader trend among clinical laboratories to address climate change and reduce their carbon footprint. As they continue to integrate these initiatives, further details on their specific emissions and reduction strategies may emerge in the future.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 72,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 155,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 311,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Clinical Laboratories of Hawaii, LLP, Tissue-Typing and Cell Processing Lab has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.